GLPG 1205

Drug Profile

GLPG 1205

Alternative Names: GLPG-1205

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories
  • Mechanism of Action GPR84 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases
  • Discontinued Ulcerative colitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease(In volunteers) in Belgium (PO, Suspension)
  • 01 Feb 2016 Galapagos completes a phase I trial in Healthy volunteers in Belgium (PO) (NCT02623296)
  • 26 Jan 2016 Discontinued - Phase-II for Ulcerative colitis in Hungary, Czech Republic, Germany, Russia, Poland and Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top